The Mechanism and Treatment of Atherosclerosis

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 1568

Special Issue Editor


E-Mail Website
Guest Editor
Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Hindenburgdamm 30, 12203 Berlin, Germany
Interests: atherosclerosis; atrial fibrillation; gut-heart axis; cardiogenic shock; hemostasis; thrombo-inflammation

Special Issue Information

Dear Colleagues,

During the last decades, a broad spectrum of therapeutic targets, therapeutics, and differential treatment regimes have evolved in the field of atherogenesis and adverse cardiovascular events. The challenge of the next years is to translate these findings into clinical practice to guide primary and secondary prevention.  

This Special Issue on "The Mechanisms and Treatment of Atherosclerosis" welcomes original research articles and state-of-the-art reviews in this field. Papers should provide novel data or gather current knowledge regarding a personalized/individualized therapeutical approach, with a special focus on:

  • Pathogenesis, mechanisms, and complications of atherosclerotic cardiovascular disease (ASCVD)
  • Translational medical research
  • Novel targets
  • Biomarker discovery and early diagnosis research
  • Drug discovery and drug development, biomedicine, and pharmacotherapy
  • Nanobiotechnological advances in biomedicine

Dr. Julian Friebel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atherogenesis
  • acute coronary syndrome
  • plaque erosion
  • plaque rupture
  • cardiogenic shock
  • resuscitation
  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • MACE
  • residual risk
  • coagulation
  • hemostasis
  • platelets
  • thrombo-inflammation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 991 KiB  
Review
C-Reactive Protein: The Quintessential Marker of Systemic Inflammation in Coronary Artery Disease—Advancing toward Precision Medicine
by Emanuel Amezcua-Castillo, Héctor González-Pacheco, Arturo Sáenz-San Martín, Pablo Méndez-Ocampo, Iván Gutierrez-Moctezuma, Felipe Massó, Daniel Sierra-Lara, Rashidi Springall, Emma Rodríguez, Alexandra Arias-Mendoza and Luis M. Amezcua-Guerra
Biomedicines 2023, 11(9), 2444; https://doi.org/10.3390/biomedicines11092444 - 02 Sep 2023
Cited by 2 | Viewed by 1351
Abstract
Atherosclerotic cardiovascular disease (CVD) remains the leading cause of mortality worldwide. While conventional risk factors have been studied and managed, CVD continues to pose a global threat. Risk scoring systems based on these factors have been developed to predict acute coronary syndromes and [...] Read more.
Atherosclerotic cardiovascular disease (CVD) remains the leading cause of mortality worldwide. While conventional risk factors have been studied and managed, CVD continues to pose a global threat. Risk scoring systems based on these factors have been developed to predict acute coronary syndromes and guide therapeutic interventions. However, traditional risk algorithms may not fully capture the complexities of individual patients. Recent research highlights the role of inflammation, particularly chronic low-grade inflammation, in the pathogenesis of coronary artery disease (CAD). C-reactive protein (CRP) is an inflammatory molecule that has demonstrated value as a predictive marker for cardiovascular risk assessment, both independently and in conjunction with other parameters. It has been incorporated into risk assessment algorithms, enhancing risk prediction and guiding therapeutic decisions. Pharmacological interventions with anti-inflammatory properties, such as statins, glucagon-like peptide-1 agonists, and interleukin-1 inhibitors, have shown promising effects in reducing both cardiovascular risks and CRP levels. This manuscript provides a comprehensive review of CRP as a marker of systemic inflammation in CAD. By exploring the current knowledge surrounding CRP and its implications for risk prediction and therapeutic interventions, this review contributes to the advancement of personalized cardiology and the optimization of patient care. Full article
(This article belongs to the Special Issue The Mechanism and Treatment of Atherosclerosis)
Show Figures

Figure 1

Back to TopTop